Nivolumab + ipilimumab received United States Food and Drug Administration (FDA) regulatory approval in May 2020 for previously untreated metastatic NSCLC with PD-L1 TPS ≥1% and no EGFR/ALK aberrations [3,8]. Here, EGFR is linked to non-small cell lung carcinoma.